SKN | Bank of America Reaffirms Buy Rating on Insulet as Long-Term Growth Outlook Remains Intact

Key Takeaways:

• Bank of America Securities maintained its Buy rating on Insulet with a $208 price target.
• The firm believes current market concerns around slower U.S. Omnipod growth are already reflected in the stock price.
• Analysts continue to see a pathway toward strong revenue growth and more than 25% annual earnings-per-share expansion.

 

Bank of America Securities has reaffirmed its Buy rating on Insulet Corporation, signaling continued confidence in the medical device company’s long-term growth prospects despite concerns surrounding the pace of growth in its flagship Omnipod insulin delivery platform.

The firm’s $208 price target reflects a belief that much of the recent caution surrounding Omnipod adoption in the United States has already been incorporated into the company’s valuation. For investors, the analysis suggests that future growth opportunities may outweigh current market concerns.

Insulet remains one of the leading innovators in diabetes management technology, serving patients who require insulin-dependent treatment through its wearable, tubeless insulin delivery systems.

Why Bank of America Remains Optimistic

According to analyst Travis Steed, Insulet’s current valuation appears to reflect expectations for a slower growth profile in the U.S. market. However, Bank of America’s forecasts indicate that the company can still achieve mid-teens to high-teens revenue growth through 2027 and 2028.

The firm’s projections assume some moderation in Insulet’s share of new insulin pump users, making the forecast relatively conservative. Even under these assumptions, analysts believe the company can continue generating attractive growth rates as demand for advanced diabetes management solutions expands globally.

This outlook supports the view that Insulet’s long-term growth story remains largely intact.

Omnipod Continues to Drive Growth

At the center of the investment thesis is Omnipod, Insulet’s wearable insulin delivery platform designed to simplify diabetes management for patients.

Unlike traditional insulin pumps, Omnipod offers a tubeless design that many users find more convenient and easier to integrate into daily life. The product has become a major growth driver as healthcare providers increasingly adopt advanced diabetes technologies that improve patient outcomes and quality of life.

Bank of America noted that if Insulet successfully maintains its share of new patient starts and benefits from faster industry expansion, revenue growth could potentially accelerate into the low-to-mid 20% range.

Such an outcome would provide meaningful upside beyond current expectations.

Earnings Growth Remains a Key Attraction

In addition to revenue growth, analysts are focused on Insulet’s earnings potential.

Bank of America projects that the company could grow earnings per share at a compound annual rate exceeding 25%. This level of earnings expansion would place Insulet among the faster-growing companies within the broader medical technology sector.

As manufacturing scales and operating efficiencies improve, investors will be closely monitoring margins, profitability, and cash flow generation alongside revenue growth.

The combination of recurring patient demand and expanding adoption of insulin delivery technology continues to support the long-term investment case.

What Investors Should Watch

Future performance will likely depend on Omnipod adoption rates, competitive developments within the insulin pump market, reimbursement trends, and broader healthcare technology adoption.

Investors should also monitor international expansion efforts, new product launches, and management’s ability to maintain market share as competition increases.

While short-term growth fluctuations may create volatility, analysts remain focused on the company’s long-term opportunity within the growing diabetes care market.

Confidential Advisory

Confidential Advisory: Investors evaluating healthcare technology companies should focus on patient adoption trends, reimbursement support, product differentiation, and long-term market expansion rather than short-term quarterly fluctuations. Companies that successfully combine clinical effectiveness with ease of use often build durable competitive advantages that support sustained growth over many years.

Closing Insights

The global diabetes management market continues to expand as healthcare systems increasingly embrace technology-driven solutions.

Insulet’s Omnipod platform remains well positioned to benefit from this trend, particularly as patients seek more convenient and personalized treatment options.

Bank of America’s continued confidence reflects a belief that the company’s long-term growth drivers remain intact despite near-term market concerns.

For investors, the key question is whether Insulet can continue converting technological leadership into sustained market share gains and earnings growth.

For a confidential discussion regarding retail banking strategy, insurance distribution models, customer loyalty ecosystems, digital financial services, or cross-border financial innovation opportunities, contact our senior advisory team.